Mesalamine (Lialda) - Global Top Players Market Share and Ranking 2025- YH Research

日本语 | 中文

Home > Reports >Medical Care > Mesalamine (Lialda) - Global Top Players Market Share and Ranking 2025

Mesalamine (Lialda) - Global Top Players Market Share and Ranking 2025

Publication Date: 2025-09-19
Report Id: 2424558
Industry: Medical Care
Report Page: 105
Chart: 105

PDF Download

Publication Date: 2025-09-19
Report Id: 2424558
Industry: Medical Care
Report Page: 105
Chart: 105

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 Mesalamine (Lialda) Definition
1.2 Global Mesalamine (Lialda) Market Size and Forecast
1.3 China Mesalamine (Lialda) Market Size and Forecast
1.4 Share of China Mesalamine (Lialda) Market with Respect to the Global Market
1.5 Mesalamine (Lialda) Market Size: China VS Global Growth Rate, 2020-2031
1.6 Mesalamine (Lialda) Market Dynamics
1.6.1 Mesalamine (Lialda) Market Drivers
1.6.2 Mesalamine (Lialda) Market Restraints
1.6.3 Mesalamine (Lialda) Industry Trends
1.6.4 Mesalamine (Lialda) Industry Policy

2 Global Leading Players and Market Share
2.1 By Revenue of Mesalamine (Lialda), Global Market Share by Company, 2020-2025
2.2 Global Mesalamine (Lialda) Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.3 Global Mesalamine (Lialda) Concentration Ratio
2.4 Global Mesalamine (Lialda) Mergers & Acquisitions, Expansion Plans
2.5 Global Mesalamine (Lialda) Major Companies Product Type
2.6 Head Office and Area Served of Key Players

3 China Leading Players, Market Share and Ranking
3.1 By Revenue of Mesalamine (Lialda), China Market Share by Company, 2020-2025
3.2 China Mesalamine (Lialda) Mesalamine (Lialda) Participants, Market Position (Tier 1, Tier 2, and Tier 3)

4 Industry Chain Analysis
4.1 Mesalamine (Lialda) Industry Chain
4.2 Mesalamine (Lialda) Upstream Analysis
4.2.1 Mesalamine (Lialda) Core Raw Materials
4.2.2 Main Manufacturers of Mesalamine (Lialda) Core Raw Materials
4.3 Midstream Analysis
4.4 Downstream Analysis
4.5 Mesalamine (Lialda) Production Mode
4.6 Mesalamine (Lialda) Procurement Model
4.7 Mesalamine (Lialda) Industry Sales Model and Sales Channels
4.7.1 Mesalamine (Lialda) Sales Model
4.7.2 Mesalamine (Lialda) Typical Distributors

5 Sights by Type
5.1 Mesalamine (Lialda) Classification by Type
5.1.1 Tablets
5.1.2 Capsules
5.1.3 Granule
5.1.4 Suppository
5.1.5 Enema
5.1.6 Others
5.2 by Type, Global Mesalamine (Lialda) Consumption Value & CAGR, 2020 VS 2024 VS 2031
5.3 by Type, Global Mesalamine (Lialda) Consumption Value, 2020-2031

6 Sights by Application
6.1 Mesalamine (Lialda) Segment by Application
6.1.1 Ulcerative Colitis (UC)
6.1.2 Crohn’s Disease (CD)
6.1.3 Others
6.2 by Application, Global Mesalamine (Lialda) Consumption Value & CAGR, 2020 VS 2024 VS 2031
6.3 by Application, Global Mesalamine (Lialda) Consumption Value, 2020-2031

7 Sales Sights by Region
7.1 By Region, Global Mesalamine (Lialda) Consumption Value, 2020 VS 2024 VS 2031
7.2 By Region, Global Mesalamine (Lialda) Consumption Value, 2020-2031
7.3 North America
7.3.1 North America Mesalamine (Lialda) Market Size & Forecasts, 2020-2031
7.3.2 By Country, North America Mesalamine (Lialda) Market Size Market Share
7.4 Europe
7.4.1 Europe Mesalamine (Lialda) Market Size & Forecasts, 2020-2031
7.4.2 By Country, Europe Mesalamine (Lialda) Market Size Market Share
7.5 Asia Pacific
7.5.1 Asia Pacific Mesalamine (Lialda) Market Size & Forecasts, 2020-2031
7.5.2 By Country/Region, Asia Pacific Mesalamine (Lialda) Market Size Market Share
7.6 South America
7.6.1 South AmericaMesalamine (Lialda) Market Size & Forecasts, 2020-2031
7.6.2 By Country, South America Mesalamine (Lialda) Market Size Market Share
7.7 Middle East & Africa

8 Sales Sights by Country Level
8.1 By Country, Global Mesalamine (Lialda) Market Size & CAGR, 2020 VS 2024 VS 2031
8.2 By Country, Global Mesalamine (Lialda) Consumption Value, 2020-2031
8.3 United States
8.3.1 United States Mesalamine (Lialda) Market Size, 2020-2031
8.3.2 by Type, United States Mesalamine (Lialda) Consumption Value Market Share, 2024 VS 2031
8.3.3 by Application, United States Mesalamine (Lialda) Consumption Value Market Share, 2024 VS 2031
8.4 Europe
8.4.1 Europe Mesalamine (Lialda) Market Size, 2020-2031
8.4.2 by Type, Europe Mesalamine (Lialda) Consumption Value Market Share, 2024 VS 2031
8.4.3 by Application, Europe Mesalamine (Lialda) Consumption Value Market Share, 2024 VS 2031
8.5 China
8.5.1 China Mesalamine (Lialda) Market Size, 2020-2031
8.5.2 by Type, China Mesalamine (Lialda) Consumption Value Market Share, 2024 VS 2031
8.5.3 by Application, China Mesalamine (Lialda) Consumption Value Market Share, 2024 VS 2031
8.6 Japan
8.6.1 Japan Mesalamine (Lialda) Market Size, 2020-2031
8.6.2 by Type, Japan Mesalamine (Lialda) Consumption Value Market Share, 2024 VS 2031
8.6.3 by Application, Japan Mesalamine (Lialda) Consumption Value Market Share, 2024 VS 2031
8.7 South Korea
8.7.1 South Korea Mesalamine (Lialda) Market Size, 2020-2031
8.7.2 by Type, South Korea Mesalamine (Lialda) Consumption Value Market Share, 2024 VS 2031
8.7.3 by Application, South Korea Mesalamine (Lialda) Consumption Value Market Share, 2024 VS 2031
8.8 Southeast Asia
8.8.1 Southeast Asia Mesalamine (Lialda) Market Size, 2020-2031
8.8.2 by Type, Southeast Asia Mesalamine (Lialda) Consumption Value Market Share, 2024 VS 2031
8.8.3 by Application, Southeast Asia Mesalamine (Lialda) Consumption Value Market Share, 2024 VS 2031
8.9 India
8.9.1 India Mesalamine (Lialda) Market Size, 2020-2031
8.9.2 by Type, India Mesalamine (Lialda) Consumption Value Market Share, 2024 VS 2031
8.9.3 by Application, India Mesalamine (Lialda) Consumption Value Market Share, 2024 VS 2031
8.10 Middle East & Africa
8.10.1 Middle East & Africa Mesalamine (Lialda) Market Size, 2020-2031
8.10.2 by Type, Middle East & Africa Mesalamine (Lialda) Consumption Value Market Share, 2024 VS 2031
8.10.3 by Application, Middle East & Africa Mesalamine (Lialda) Consumption Value Market Share, 2024 VS 2031

9 Company Profile
9.1 Takeda
9.1.1 Takeda Company Information, Head Office, Market Area, and Industry Position
9.1.2 Takeda Company Profile and Main Business
9.1.3 Takeda Mesalamine (Lialda) Models, Specifications, and Application
9.1.4 Takeda Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.1.5 Takeda Recent Developments
9.2 Ferring
9.2.1 Ferring Company Information, Head Office, Market Area, and Industry Position
9.2.2 Ferring Company Profile and Main Business
9.2.3 Ferring Mesalamine (Lialda) Models, Specifications, and Application
9.2.4 Ferring Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.2.5 Ferring Recent Developments
9.3 AbbVie
9.3.1 AbbVie Company Information, Head Office, Market Area, and Industry Position
9.3.2 AbbVie Company Profile and Main Business
9.3.3 AbbVie Mesalamine (Lialda) Models, Specifications, and Application
9.3.4 AbbVie Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.3.5 AbbVie Recent Developments
9.4 Bausch Health
9.4.1 Bausch Health Company Information, Head Office, Market Area, and Industry Position
9.4.2 Bausch Health Company Profile and Main Business
9.4.3 Bausch Health Mesalamine (Lialda) Models, Specifications, and Application
9.4.4 Bausch Health Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.4.5 Bausch Health Recent Developments
9.5 Teva
9.5.1 Teva Company Information, Head Office, Market Area, and Industry Position
9.5.2 Teva Company Profile and Main Business
9.5.3 Teva Mesalamine (Lialda) Models, Specifications, and Application
9.5.4 Teva Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.5.5 Teva Recent Developments
9.6 Mylan
9.6.1 Mylan Company Information, Head Office, Market Area, and Industry Position
9.6.2 Mylan Company Profile and Main Business
9.6.3 Mylan Mesalamine (Lialda) Models, Specifications, and Application
9.6.4 Mylan Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.6.5 Mylan Recent Developments
9.7 Dr. Reddy's Laboratories
9.7.1 Dr. Reddy's Laboratories Company Information, Head Office, Market Area, and Industry Position
9.7.2 Dr. Reddy's Laboratories Company Profile and Main Business
9.7.3 Dr. Reddy's Laboratories Mesalamine (Lialda) Models, Specifications, and Application
9.7.4 Dr. Reddy's Laboratories Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.7.5 Dr. Reddy's Laboratories Recent Developments
9.8 Lupin Limited
9.8.1 Lupin Limited Company Information, Head Office, Market Area, and Industry Position
9.8.2 Lupin Limited Company Profile and Main Business
9.8.3 Lupin Limited Mesalamine (Lialda) Models, Specifications, and Application
9.8.4 Lupin Limited Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.8.5 Lupin Limited Recent Developments
9.9 Sun Pharma
9.9.1 Sun Pharma Company Information, Head Office, Market Area, and Industry Position
9.9.2 Sun Pharma Company Profile and Main Business
9.9.3 Sun Pharma Mesalamine (Lialda) Models, Specifications, and Application
9.9.4 Sun Pharma Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.9.5 Sun Pharma Recent Developments
9.10 Sandoz
9.10.1 Sandoz Company Information, Head Office, Market Area, and Industry Position
9.10.2 Sandoz Company Profile and Main Business
9.10.3 Sandoz Mesalamine (Lialda) Models, Specifications, and Application
9.10.4 Sandoz Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.10.5 Sandoz Recent Developments
9.11 Dr.Falk Pharma
9.11.1 Dr.Falk Pharma Company Information, Head Office, Market Area, and Industry Position
9.11.2 Dr.Falk Pharma Company Profile and Main Business
9.11.3 Dr.Falk Pharma Mesalamine (Lialda) Models, Specifications, and Application
9.11.4 Dr.Falk Pharma Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.11.5 Dr.Falk Pharma Recent Developments
9.12 Zydus Healthcare
9.12.1 Zydus Healthcare Company Information, Head Office, Market Area, and Industry Position
9.12.2 Zydus Healthcare Company Profile and Main Business
9.12.3 Zydus Healthcare Mesalamine (Lialda) Models, Specifications, and Application
9.12.4 Zydus Healthcare Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.12.5 Zydus Healthcare Recent Developments
9.13 Shanghai Pharmaceuticals
9.13.1 Shanghai Pharmaceuticals Company Information, Head Office, Market Area, and Industry Position
9.13.2 Shanghai Pharmaceuticals Company Profile and Main Business
9.13.3 Shanghai Pharmaceuticals Mesalamine (Lialda) Models, Specifications, and Application
9.13.4 Shanghai Pharmaceuticals Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.13.5 Shanghai Pharmaceuticals Recent Developments
9.14 Sunflower Pharmaceutical Group
9.14.1 Sunflower Pharmaceutical Group Company Information, Head Office, Market Area, and Industry Position
9.14.2 Sunflower Pharmaceutical Group Company Profile and Main Business
9.14.3 Sunflower Pharmaceutical Group Mesalamine (Lialda) Models, Specifications, and Application
9.14.4 Sunflower Pharmaceutical Group Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.14.5 Sunflower Pharmaceutical Group Recent Developments
9.15 Sinotherapeutics
9.15.1 Sinotherapeutics Company Information, Head Office, Market Area, and Industry Position
9.15.2 Sinotherapeutics Company Profile and Main Business
9.15.3 Sinotherapeutics Mesalamine (Lialda) Models, Specifications, and Application
9.15.4 Sinotherapeutics Mesalamine (Lialda) Revenue and Gross Margin, 2020-2025
9.15.5 Sinotherapeutics Recent Developments

10 Conclusion

11 Appendix
11.1 Research Methodology
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Market Estimation Model
11.4 Disclaimer

According to YH Research, the global market for Mesalamine (Lialda) should grow from US$ 1942 million in 2024 to US$ 2490 million by 2031, with a CAGR of 3.9% for the period of 2025-2031.

Mesalamine (brand name: Lialda) is an anti-inflammatory drug belonging to the class of aminosalicylates (5-aminosalicylic acid, 5-ASA). It is primarily used to induce and maintain remission in patients with mild to moderate ulcerative colitis. Lialda is an extended-release oral formulation of mesalamine, designed to deliver the drug throughout the colon for localized anti-inflammatory effects.

Mesalamine (Lialda)

According to YH Research, the global market for Mesalamine (Lialda) should grow from US$ 1942 million in 2024 to US$ 2490 million by 2031, with a CAGR of 3.9% for the period of 2025-2031.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

The global prevalence of IBD is rising, particularly in developed regions like North America and Europe, and increasingly in developing nations such as China and India. This increase is largely attributed to changes in lifestyle, dietary habits, and environmental factors, which are contributing to the growing demand for mesalazine.

With ulcerative colitis being the primary indication for mesalazine, the growing number of patients with this condition is directly driving market demand.

Regional demand: North America remains the largest market, supported by high disease prevalence and advanced healthcare systems, while Asia-Pacific is emerging as the fastest-growing region due to rising awareness and healthcare access.

This report studies and analyses global Mesalamine (Lialda) status and future trends, to help determine the Mesalamine (Lialda) market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for Mesalamine (Lialda), and provides market size (US$ million) and Year-over-Year growth, considering 2024 as the base year.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

To assess the competitive environment within the market including supplier revenue, market share, and company profiles.

Highlights
(1) Global Mesalamine (Lialda) market size, history data 2020-2025, and forecast data 2026 -2031, (US$ million)
(2) Global Mesalamine (Lialda) by company, revenue, market share and industry ranking 2020-2025, (US$ million)
(3) China Mesalamine (Lialda) by company, revenue, market share and industry ranking 2020-2025, (US$ million)
(4) Global Mesalamine (Lialda) key consuming regions, consumption value and demand structure
(5) Mesalamine (Lialda) industry chains, upstream, midstream and downstream
Market segment by players, this report covers
Takeda
Ferring
AbbVie
Bausch Health
Teva
Mylan
Dr. Reddy's Laboratories
Lupin Limited
Sun Pharma
Sandoz
Dr.Falk Pharma
Zydus Healthcare
Shanghai Pharmaceuticals
Sunflower Pharmaceutical Group
Sinotherapeutics

Market segment by Type, covers
Tablets
Capsules
Granule
Suppository
Enema
Others

Market segment by Application, can be divided into
Ulcerative Colitis (UC)
Crohn’s Disease (CD)
Others

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Report Includes:
Chapter 1: to describe Mesalamine (Lialda) product scope, global consumption value, China consumption value, development opportunities, challenges, trends, and policies.
Chapter 2: Global Mesalamine (Lialda) market share and ranking of major manufacturers, revenue, 2020-2025
Chapter 3: China Mesalamine (Lialda) market share and ranking of major manufacturers, revenue, 2020-2025
Chapter 4: Mesalamine (Lialda) industry chain, upstream, medium-stream, and downstream.
Chapter 5: Segment by Type, consumption value, percent & CAGR, 2020-2031
Chapter 6: Segment by Application, consumption value, percent & CAGR, 2020-2031
Chapter 7: Segment in regional level, consumption value, percent & CAGR, 2020-2031
Chapter 8: Segment in country level, consumption value, percent & CAGR, 2020-2031
Chapter 9: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, revenue, gross margin.
Chapter 10: Conclusions